Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways.
Bitner RS
,
Bunnelle WH
,
Anderson DJ
,
Briggs CA
,
Buccafusco J
,
Curzon P
,
Decker MW
,
Frost JM
,
Gronlien JH
,
Gubbins E
,
Li J
,
Malysz J
,
Markosyan S
,
Marsh K
,
Meyer MD
,
Nikkel AL
,
Radek RJ
,
Robb HM
,
Timmermann D
,
Sullivan JP
,
Gopalakrishnan M
.
???displayArticle.abstract???
The alpha7 nicotinic acetylcholine receptor (nAChR) plays an important role in cognitive processes and may represent a drug target for treating cognitive deficits in neurodegenerative and psychiatric disorders. In the present study, we used a novel alpha7 nAChR-selective agonist, 2-methyl-5-(6-phenyl-pyridazin-3-yl)-octahydro-pyrrolo[3,4-c]pyrrole (A-582941) to interrogate cognitive efficacy, as well as examine potential cellular mechanisms of cognition. Exhibiting high affinity to native rat (Ki = 10.8 nM) and human (Ki = 16.7 nM) alpha7 nAChRs, A-582941 enhanced cognitive performance in behavioral assays including the monkey delayed matching-to-sample, rat social recognition, and mouse inhibitory avoidance models that capture domains of working memory, short-term recognition memory, and long-term memory consolidation, respectively. In addition, A-582941 normalized sensory gating deficits induced by the alpha7 nAChR antagonist methyllycaconitine in rats, and in DBA/2 mice that exhibit a natural sensory gating deficit. Examination of signaling pathways known to be involved in cognitive function revealed that alpha7 nAChR agonism increased extracellular-signal regulated kinase 1/2 (ERK1/2) phosphorylation in PC12 cells. Furthermore, increases in ERK1/2 and cAMP response element-binding protein (CREB) phosphorylation were observed in mouse cingulate cortex and/or hippocampus after acute A-582941 administration producing plasma concentrations in the range of alpha7 binding affinities and behavioral efficacious doses. The MEK inhibitor SL327 completely blocked alpha7 agonist-evoked ERK1/2 phosphorylation. Our results demonstrate that alpha7 nAChR agonism can lead to broad-spectrum efficacy in animal models at doses that enhance ERK1/2 and CREB phosphorylation/activation and may represent a mechanism that offers potential to improve cognitive deficits associated with neurodegenerative and psychiatric diseases, such as Alzheimer's disease and schizophrenia.
Adams,
Molecular psychology: roles for the ERK MAP kinase cascade in memory.
2002, Pubmed
Adams,
Molecular psychology: roles for the ERK MAP kinase cascade in memory.
2002,
Pubmed
Adams,
Alpha7-nicotinic receptor expression and the anatomical organization of hippocampal interneurons.
2001,
Pubmed
Bartus,
On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis.
2000,
Pubmed
Berg,
Nicotinic alpha 7 receptors: synaptic options and downstream signaling in neurons.
2002,
Pubmed
Biton,
SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile.
2007,
Pubmed
,
Xenbase
Briggs,
Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by agonists.
1998,
Pubmed
,
Xenbase
Buccafusco,
A computer-assisted cognitive test battery for aged monkeys.
2002,
Pubmed
Carlezon,
The many faces of CREB.
2005,
Pubmed
Court,
Nicotinic receptor abnormalities in Alzheimer's disease.
2001,
Pubmed
Couturier,
A neuronal nicotinic acetylcholine receptor subunit (alpha 7) is developmentally regulated and forms a homo-oligomeric channel blocked by alpha-BTX.
1990,
Pubmed
,
Xenbase
Curzon,
Antisense knockdown of the rat alpha7 nicotinic acetylcholine receptor produces spatial memory impairment.
2006,
Pubmed
Dajas-Bailador,
Nicotine activates the extracellular signal-regulated kinase 1/2 via the alpha7 nicotinic acetylcholine receptor and protein kinase A, in SH-SY5Y cells and hippocampal neurones.
2002,
Pubmed
Dalley,
Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates.
2004,
Pubmed
Favata,
Identification of a novel inhibitor of mitogen-activated protein kinase kinase.
1998,
Pubmed
Fisher,
M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.
2003,
Pubmed
Freedman,
The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia.
2000,
Pubmed
Gault,
Comparison of polymorphisms in the alpha7 nicotinic receptor gene and its partial duplication in schizophrenic and control subjects.
2003,
Pubmed
Germano,
Working memory and learning in early Alzheimer's disease.
2005,
Pubmed
Giovannini,
The role of the extracellular signal-regulated kinase pathway in memory encoding.
2006,
Pubmed
Gray,
Hippocampal synaptic transmission enhanced by low concentrations of nicotine.
1996,
Pubmed
Hajós,
The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats.
2005,
Pubmed
Harris,
Effects of nicotine on cognitive deficits in schizophrenia.
2004,
Pubmed
Heerssen,
Location, location, location: a spatial view of neurotrophin signal transduction.
2002,
Pubmed
Jessen,
Sensory gating deficit expressed by a disturbed suppression of the P50 event-related potential in patients with Alzheimer's disease.
2001,
Pubmed
Kása,
The cholinergic system in Alzheimer's disease.
1997,
Pubmed
Levin,
Nicotinic acetylcholine involvement in cognitive function in animals.
1998,
Pubmed
Levin,
Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization.
2006,
Pubmed
Martí Barros,
Participation of hippocampal nicotinic receptors in acquisition, consolidation and retrieval of memory for one trial inhibitory avoidance in rats.
2004,
Pubmed
Miyashita,
Cognitive memory: cellular and network machineries and their top-down control.
2004,
Pubmed
Nakayama,
Nicotine-induced phosphorylation of extracellular signal-regulated protein kinase and CREB in PC12h cells.
2001,
Pubmed
Nordberg,
Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications.
2001,
Pubmed
Pabreza,
[3H]cytisine binding to nicotinic cholinergic receptors in brain.
1991,
Pubmed
Pichat,
SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.
2007,
Pubmed
Potter,
Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease.
1999,
Pubmed
Radcliffe,
Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons.
1999,
Pubmed
Rezvani,
Cognitive effects of nicotine.
2001,
Pubmed
Ring,
Transcriptional profiling of brain-derived-neurotrophic factor-induced neuronal plasticity: a novel role for nociceptin in hippocampal neurite outgrowth.
2006,
Pubmed
Séguéla,
Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium.
1993,
Pubmed
,
Xenbase
Selcher,
A necessity for MAP kinase activation in mammalian spatial learning.
1999,
Pubmed
Stassen,
Schizophrenia and smoking: evidence for a common neurobiological basis?
2000,
Pubmed
Stevens,
Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animal models.
1997,
Pubmed
Stevens,
Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice.
1998,
Pubmed
Trumbull,
High throughput electrophysiology using a fully automated, multiplexed recording system.
2003,
Pubmed
,
Xenbase
Van Kampen,
AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors.
2004,
Pubmed
White,
Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease.
1999,
Pubmed
Yu,
High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques.
2005,
Pubmed
